Talk to an expert
Envelope Linkedin

Explore Starodub latest updates

Get in touch
View our whitepapers
  • Updates

The most expensive regulatory deficiency is the one you discover after submitting your dossier. How much could a regulatory delay cost your development program?
  • Updates

Women’s Health is Finally Moving Towards the Regulatory Attention it Deserves
  • Updates

Your Product Might Be Safe. Is Your IFU?
  • Updates

EU drug-device combination products (DDC): regulatory aspects start early
  • Updates

Investing in ATMP or Biologics? Regulatory risk is value critical.
  • Updates

Four challenges from MEB’s State of Implementation report
  • Updates

Transitioning to the EU In Vitro Diagnostic Regulation: is your IVD technical documentation ready for submission?
  • Updates

Starodub eCTD Team
  • Updates

Medical device market access in the EU: national obligations beyond EUDAMED
  • Updates

Regulatory support for ATMP & Biologics developers
  • Updates

Looking for regulatory expertise to move your (Bio)Pharmaceutical project forward?
  • Updates

28 May is almost here — is your organization EUDAMED‑ready?
  • Updates

Key revisions of Policy Document for Parallel Import of Medicines
  • Updates

Before strategy is written, it is already made
  • Updates

EMA Centralised Procedure – Analysis of Marketing Authorisation Applications
  • Updates

Respiratory Syncytial Virus (RSV) and its growing public health impact.
  • Updates

EMA strengthens PRIME: New tools to accelerate breakthrough medicines in Europe
  • Updates

EMA Updates Guideline on Chemistry of Active Substances
Load more updates
Jolanda Lamers-Lemmers
Management team member - Senior RA Consultant
Jolanda Lamers-Lemmers

Let's Connect

Talk to an expert